A Multi-Centre, Randomized, Double-Blind, Placebo Controlled Pilot Trial to Assess the Efficacy, Safety, and Tolerability of SPM 927 in Subjects With Postherpetic Neuralgia (PHN).

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 28, 2002

Primary Completion Date

December 31, 2002

Study Completion Date

January 31, 2003

Conditions

Postherpetic Neuralgia

Interventions

DRUG

SPM927/Lacosamide

SPM927 (film-coated tablets, 25/50/100mg per tablet), dosage up to 600mg/day, intake in the morning and in the evening, intake for 11 weeks

OTHER

Placebo

Placebo tablets two times a day for 10 weeks